PRESS RELEASE: EORTC and CDDF announce new collaboration
CDDF provides a neutral platform to stimulate interactions between all [...]
MINDACT (EORTC 10041/BIG3-04): Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients GalleryMINDACT (EORTC 10041/BIG3-04): Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients
MINDACT (EORTC 10041/BIG3-04): Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients
The long-term results of the MINDACT (EORTC 10041/BIG3-04) study were [...]
EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up GalleryEORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up
EORTC 1325-MG/Keynote 054: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results at three-year median follow-up
Today, Professor A.M.M Eggermont presented the updated efficacy results of [...]
EORTC researchers discover a treatment for drug-resistant GIST
By Mary Rice, EORTC Communication Consultant Although there are effective [...]
EORTC abstracts selected at ASCO Annual meeting 2020
5 EORTC abstracts were selected for the ASCO annual meeting [...]
Evolutions in Oncology Clinical Trials
By Jan Bogaerts, PhD, Scientific Director, EORTC HQ, Brussels, Belgium [...]
Unmasking P-values
By Laurence Collette, PhD, Scientific Development Leader, EORTC HQ, Brussels, [...]
Radiation oncology priorities for clinical trials
By Davi Kaur, Head of Communication, EORTC HQ, Brussels, Belgium [...]
The JCOG- EORTC symposium 15 February 2020
In 2017, EORTC and JCOG, (Japan Clinical Oncology Group), established [...]
EORTC 1809 STRASS II trial in retroperitoneal sarcoma receives support by the Anticancer Fund
Brussels, April 28, 2020 – EORTC 1809 STRASS II trial [...]
